Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US8816242098

SecurityTEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
InstitutionPointState Capital LP
ManagerZach Schreiber
Latest Disclosed Ownership1,973,782 shares
Latest Disclosed Value $ 59,450,314
PointState Capital LP ownership in TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)

On May 15, 2026 - PointState Capital LP filed a 13F-HR form disclosing ownership of 1,973,782 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) (US:TEVA) valued at $59,450,314 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 3,793,986 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock). This represents a change in shares of -47.98% during the quarter. The current value of the position is $67,957,314 USD.

PointState Capital LP has a history of taking positions in derivatives of the underlying security (TEVA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 1,973,782 -1,820,204 -47.98 59,450 -49.79 0.7444
2026-02-17 2025-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 3,793,986 -16,918,412 -81.68 118,410 -71.70 1.7436
2025-11-14 2025-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 20,712,398 0 0.00 418,390 20.53 6.2461
2025-08-14 2025-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 20,712,398 5,580,910 36.88 347,140 49.26 5.2927
2025-05-15 2025-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 15,131,488 1,605,013 11.87 232,571 -21.99 3.3705
2025-02-14 2024-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 13,526,475 3,768,131 38.61 298,124 69.54 5.4346
2024-11-14 2024-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 9,758,344 611,621 6.69 175,845 18.31 3.1906
2024-08-14 2024-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 9,146,723 4,041,754 79.17 148,634 106.35 3.2303
2024-05-15 2024-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 5,104,969 5,104,969 72,031 1.2326
2018-11-14 2018-09-30 13F Teva Pharmaceutical Inds SPONSORED ADR 881624209 0 -6,654,040 -100.00 0 -100.00
2018-08-14 2018-06-30 13F Teva Pharmaceutical Inds SPONSORED ADR 881624209 6,654,040 6,654,040 161,826 1.8311
2017-02-14 2016-12-31 13F Teva Pharmaceutical Inds ADR 881624209 0 -9,033,053 -100.00 0 -100.00
2016-11-14 2016-09-30 13F Teva Pharmaceutical Inds ADR 881624209 9,033,053 -5,918,607 -39.58 415,611 -44.66 4.2913
2016-08-15 2016-06-30 13F Teva Pharm Ind's ADR 881624209 14,951,660 6,679,082 80.74 751,022 69.66 15.4741
2016-05-16 2016-03-31 13F Teva Pharm Ind's SPON ADR 881624209 8,272,578 -816,931 -8.99 442,666 -25.81 11.9297
2016-02-16 2015-12-31 13F Teva Pharm Ind's ADR 881624209 9,089,509 4,137,079 83.54 596,635 113.38 15.1639
2015-11-16 2015-09-30 13F Teva Pharm Ind's ADR 881624209 4,952,430 -4,753,161 -48.97 279,614 -51.25 7.8215
2015-08-14 2015-06-30 13F Teva Pharm Ind's ADR 881624209 9,705,591 -604,374 -5.86 573,600 -10.70 6.7050
2015-05-15 2015-03-31 13F Teva Pharm Ind's ADR 881624209 10,309,965 2,216,808 27.39 642,311 38.00 8.6904
2015-02-17 2014-12-31 13F Teva Pharm Ind's ADR 881624209 8,093,157 -2,297,024 -22.11 465,437 -16.66 7.9277
2014-11-14 2014-09-30 13F Teva Pharm Ind's ADR 881624209 10,390,181 -2,084,924 -16.71 558,472 -14.60 10.1258
2014-08-14 2014-06-30 13F Teva Pharm'l Ind's ADR 881624209 12,475,105 -261,395 -2.05 653,945 -2.83 8.2190
2014-05-15 2014-03-31 13F Teva Pharm'l Ind's ADR 881624209 12,736,500 3,291,100 34.84 672,997 77.77 10.7061
2014-02-14 2013-12-31 13F Teva Pharm Ind's ADR 881624209 9,445,400 9,445,400 378,572 4.7825
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 3,672,100 0.00 114,606 54.51 n/a n/a n/a
2025-11-14 2025-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 3,672,100 0.00 74,176 20.53 n/a n/a n/a
2025-08-14 2025-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 3,672,100 0.00 61,544 9.04 n/a n/a n/a
2025-05-15 2025-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 3,672,100 46.88 56,440 2.43 n/a n/a n/a
2025-02-14 2024-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 2,500,000 0.00 55,100 22.31 n/a n/a n/a
2024-11-14 2024-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 2,500,000 0.00 45,050 10.89 n/a n/a n/a
2024-08-14 2024-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS Call 2,500,000 40,625 n/a n/a n/a
2017-02-14 2016-12-31 13F Teva Pharmaceutical Inds ADR Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-11-14 2016-09-30 13F Teva Pharmaceutical Inds ADR Call 36,500 1,679 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.